论文部分内容阅读
目的观察前列地尔联合缬沙坦治疗早期糖尿病肾病的临床疗效。方法从本院2011年1月~2013年1月内分泌科收治的糖尿病肾病患者中选取60例,其中30例给予前列地尔联合缬沙坦治疗,标记为实验组;30例仅给予前列地尔治疗,标记为对照组,均为4周/疗程。结果治疗2疗程后实验组显效18例,无效6例,总有效率80%;对照组显效12例,无效10例,总有效率66.7%。差异具有统计学意义(P<0.05);实验组副作用较对照组少,差异无统计学意义(P>0.05)。结论应用前列地尔联合缬沙坦治疗早期糖尿病肾病疗效显著,无明显不良反应,值得临床大力推广。
Objective To observe the clinical efficacy of alprostadil in combination with valsartan in the treatment of early diabetic nephropathy. Methods Sixty patients with diabetic nephropathy were admitted to Department of Endocrinology from January 2011 to January 2013 in our hospital. Thirty of them were treated with alprostadil combined with valsartan, which was marked as experimental group. Thirty patients were given only alprostadil Treatment, marked as control group, are 4 weeks / course of treatment. Results After 2 courses of treatment, 18 cases were markedly effective in the experimental group, 6 cases were ineffective and the total effective rate was 80%. In the control group, 12 cases were markedly effective and 10 cases were ineffective. The total effective rate was 66.7%. The differences were statistically significant (P <0.05). The side effects in the experimental group were less than those in the control group, with no significant difference (P> 0.05). Conclusions The application of alprostadil combined with valsartan in the treatment of early diabetic nephropathy has obvious curative effect and no obvious adverse reactions, which is worth to be popularized clinically.